Biogen Inc. (BIIB) – Limited expectations from Alzheimer’s drug

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Biogen Inc. (BIIB) (Q4FY22)

Highlights

Biogen Inc revenue was $10,173.4mn for 2022, representing an $808.3mn, or 7.4%, decrease compared to $10,981.7mn in 2021. The revenue was $2,544mn in Q4FY22.

In FY22, the sales beat was largely attributed to the spinal muscular atrophy treatment, Spinraza, which saw a 4% rise in revenue to $458.8mn. However, sales of Tecfidera, Biogen’s multiple sclerosis drug, were mixed, beating some expectations but missing others due to generic competition.

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 34

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates